 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 436 | 回復: 0 | ||
liushuai8608木蟲 (小有名氣)
|
[求助]
醫(yī)學類干細胞與關節(jié)炎臨床實驗設計
|
|
41. IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.. 1) Agency &Identifier Agency: D.B.F. Saris, UMC Utrecht (First received: January 13, 2014 Last updated: July 17, 2014 Last verified: July 2014) Identifier：NCT02037204 2) Purpose Articular cartilage defects in the knee have a poor intrinsic healing capacity and may lead to functional disability and osteoarthritis. Cartilage cell therapy using autologous chondrocyte implantation (ACI) has been established as the first advanced treatment therapy medicinal product. Although this technique has achieved good mid-term results, it is a costly and extensive two-stage procedure which is limited by the number of chondrocytes obtained by biopsy and the dedifferentiation resulting from the expansion phase. Therefore, there is a need for improvement. A new cartilage repair technique should aim at decreasing surgical trauma, lowering complexity, improving logistics and cost-effectiveness while retaining or improving clinical outcome. Direct contact between mesenchymal stromal cells (MSCs) and dedifferentiated articular chondrocytes in vitro showed improvement of the chondrogenic phenotype of dedifferentiated articular chondrocytes. In addition, preserving the pericellular matrix of chondrocytes improves cartilage formation. These chondrons (chondrocytes with their pericellular matrix) have shown improved cartilage formation when combined with allogeneic MSCs in extensive preclinical studies. The cells are mixed with fibrin cell carrier and applied to the cartilage lesion within one surgical procedure. This will reduce patient morbidity and improve patient care through immediate transplantation of a potent cell-based cartilage product. This is a phase I/II prospective monocenter study to evaluate the safety and feasibility of the IMPACT for treatment of focal articular cartilage lesions of the knee. Condition Intervention Phase Foreign-Body Reaction Inflammation Effusion (L) Knee Knee Pain Swelling Other: Cartilage repair surgery Phase 1 Phase 2 Arms Assigned Interventions Experimental: Cartilage repair surgery Single-stage cartilage repair surgery using autologous chondrons and allogeneic MSCs in a fibrin glue carrier. Other: Cartilage repair surgery Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs Other Names: Single-stage Cartilage repair IMPACT 3) Criteria Inclusion Criteria: • Age >18 and <45 years old • Symptomatic isolated full-thickness articular cartilage lesion on the femoral condyle or trochlea. • Size 2 - 8 cm2 • Intact anterior cruciate ligament Exclusion Criteria: • (History of) osteoarthritis, defined as Kellgren-Lawrence grade >3 as determined from appropriate X-ray. • Concomitant inflammatory disease that affects the joint (rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis) • (History of) Septic arthritis. • Malalignment requiring an osteotomy. • (History of) total menisectomy in the target knee joint. • Any surgery in the knee joint 6 months prior to study inclusion. • Risk groups for MRI scanning due to the magnetic field like patients with pacemakers, nerve stimulators, metal particles, stents, clips or implants, (possible) pregnancy or breast feeding. • Patients with severe anxiety for MRI scans and/or needles 4) Outcome Measures Primary Outcome Measures: • Safety [ Time Frame: Multiple time points up to 18 months ] [ Designated as safety issue: Yes ] Adverse event rate non-inferior to standard treatment (autologous chondrocyte implantation) and leads to no serious adverse events such as a immunological response. Secondary Outcome Measures: • Clinical improvement [ Time Frame: 18 months ] [ Designated as safety issue: No ] Clinical improvement as measured by patient reported outcome scores. Other Outcome Measures: • Structural repair [ Time Frame: 12 months ] [ Designated as safety issue: No ] To examine parameters of structural repair at one year after treatment using MRI and a second-look arthroscopy. • Health care use and costs [ Time Frame: 18 months ] [ Designated as safety issue: No ] To assess the healthcare use and costs related to the procedure as well as the health-related work leave during the study period. |
回復此樓» 猜你喜歡
0856調劑，是學校就去
已經有6人回復
-
288求調劑
已經有13人回復
-
288求調劑，一志愿華南理工大學071005
已經有5人回復
-
一志愿中國海洋大學，生物學，301分，求調劑
已經有5人回復
-
294求調劑材料與化工專碩
已經有12人回復
-
0817 化學工程 299分求調劑 有科研經歷 有二區(qū)文章
已經有13人回復
-
梁成偉老師課題組歡迎你的加入
已經有11人回復
-
復試調劑
已經有6人回復
-
0703化學調劑 ，六級已過，有科研經歷
已經有11人回復
-
321求調劑
已經有10人回復
相關版塊跳轉
我要訂閱樓主 liushuai8608 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 一志愿中國海洋大學，生物學，301分，求調劑 +5 | 1孫悟空 2026-03-17 | 5/250 |
|
|---|---|---|---|---|
|
|
[考研] 復試調劑 +4 | z1z2z3879 2026-03-14 | 6/300 |
|
|
[考研] 321求調劑 +8 | 何潤采123 2026-03-18 | 10/500 |
|
|
|
[考博] 東華理工大學化材專業(yè)26屆碩士博士申請 +8 | zlingli 2026-03-13 | 8/400 |
|
|
|
[考研] 324分 085600材料化工求調劑 +3 | llllkkkhh 2026-03-18 | 3/150 |
|
|
|
[考研] 287求調劑 +3 | 晨昏線與星海 2026-03-19 | 4/200 |
|
|
|
[考研] 302求調劑 +10 | 呼呼呼。。。。 2026-03-17 | 10/500 |
|
|
|
[考研] 環(huán)境工程調劑 +8 | 大可digkids 2026-03-16 | 8/400 |
|
|
|
[考研] 考研求調劑 +3 | 橘頌. 2026-03-17 | 4/200 |
|
|
|
[考研] 301求調劑 +4 | A_JiXing 2026-03-16 | 4/200 |
|
|
|
[碩博家園] 湖北工業(yè)大學 生命科學與健康學院-課題組招收2026級食品/生物方向碩士 +3 | 1喜春8 2026-03-17 | 5/250 |
|
|
|
[考研] 考研化學學碩調劑，一志愿985 +4 | 張vvvv 2026-03-15 | 6/300 |
|
|
|
[考研] 290求調劑 +3 | p asserby. 2026-03-15 | 4/200 |
|
|
|
[考研] 機械專碩325，尋找調劑院校 +3 | y9999 2026-03-15 | 5/250 |
|
|
|
[考研] 一志愿211 0703方向310分求調劑 +3 | 努力奮斗112 2026-03-15 | 3/150 |
|
|
|
[考研] 中科院材料273求調劑 +4 | yzydy 2026-03-15 | 4/200 |
|
|
|
[考研] 0703化學調劑 290分有科研經歷，論文在投 +7 | 膩膩gk 2026-03-14 | 7/350 |
|
|
|
[考研] 一志愿哈工大材料324分求調劑 +5 | 閆旭東 2026-03-14 | 5/250 |
|
|
|
[考研] ［0860］321分求調劑，ab區(qū)皆可 +4 | 寶貴熱 2026-03-13 | 4/200 |
|
|
|
[考研] 070303一志愿西北大學學碩310找調劑 +3 | d如愿上岸 2026-03-13 | 3/150 |
|